MONARCH 2: Abemaciclib with Fulvestrant in HR+/HER2 Negative Advanced Breast Cancer
Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib and fulvestrant in advanced HR+/HER2 negative breast cancer progressing patients following prior endocrine t...
Author: moasc
Added: 08/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts